The present disclosure provides one or more engineered gene effectors and systems, compositions, and methods of use thereof, wherein the one or more engineered gene effectors can be used to effect regulation of a target gene in a cell (e.g., an endogenous target gene in a cell). The one or more engineered gene effectors can be operatively coupled to a heterologous endonuclease, such as a CRISPR/Cas protein.

Disclosed herein are compositions and methods comprising epigenetic editors for epigenetic modification of B2M, as well as nucleic acids and vectors encoding the same. Also disclosed are cells epigenetically modified by the epigenetic editors.

Disclosed herein are compositions comprising allogeneic, hypoimmunogenic cell-targetable biomimetic nanovesicles (BioNVs) and methods of using the same for the treatment, prevention, and/or amelioration of HIV.

Disclosed are compositions and methods for a non-coding nucleic acid gene editing platform for the delivery of regulatory nucleic acid sequences and small peptides in a cell. In a particular aspect, provided herein is a non-coding nucleic acid gene editing platform to down regulate endogenous genes and genes from pests and pathogens causing diseases. In another aspect, the non-coding nucleic acid gene editing platform described herein is useful to deliver small regulatory peptides encoded from nucleic acid sequences embedded in a non-coding nucleic acid of a gene. More specifically, the non-coding nucleic acid gene editing platform provided herein allows using non-coding nucleic acid from any gene to deliver regulatory nucleic acids and small peptides in a cell. In another aspect, such regulatory nucleic acids and small peptides are useful to develop traits to enhance crop quality and yield.

The present invention relates to an engineered unicellular Stramenopile microalga comprising a loss of function of the homologous Seipin gene, an in vitro method of producing triacylglycerols (TAG), and uses thereof.

This invention relates to compositions and methods comprising epigenetic editors for epigenetic modification of TRAC, as well as nucleic acids and vectors encoding the same. Also disclosed are cells epigenetically modified by the epigenetic editors.

The invention provides engineered plants that are salt tolerant, methods for making these plants and uses of these plants.

Described herein is a method for editing the MHY7 gene in a cell by genome editing comprising introducing into the cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more double stranded breaks (DSBs) within or near enhancer regions of the MYH7 gene or MYH6 gene that results in deletion of one or more enhancer regions of the MYH7 gene.

The current invention provides novel approaches to the treatment of various disease states that lead to altered cytokine release or cytokine storms. These diseases include viral infections immunological and other non-immunological diseases. Specifically, the invention provides methods targeting ZHX2 including methods of inhibition, blocking or depletion of ZHX2 in order to treat various disease states.

The disclosure provides improved Cas-CLOVER systems for gene editing. In embodiments, the disclosure provides recombinant Clo051 endonucleases, or nuclease domains thereof, comprising one or more amino acid mutations (e.g. one or more amino acid substitutions at E101 and/or F44). The disclosure also provides fusion proteins, comprising: a DNA localization component, and any one of the Clo051 endonucleases disclosed herein or the nuclease domains thereof, and further provides methods of using the fusions proteins in gene editing, including introducing a double stranded break in a target nucleic acid.